Mednax, Inc (NYSE:MD) has received a consensus rating of “Hold” from the fifteen analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $64.50.

MD has been the subject of a number of recent research reports. ValuEngine downgraded shares of Mednax from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Robert W. Baird cut shares of Mednax from an “outperform” rating to a “neutral” rating and set a $72.00 price objective for the company. in a research report on Tuesday, March 21st. TheStreet cut shares of Mednax from a “b-” rating to a “c+” rating in a research report on Tuesday, May 16th. Finally, Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a research report on Thursday, May 4th.

WARNING: “Mednax, Inc (MD) Receives Average Recommendation of “Hold” from Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/17/mednax-inc-md-receives-average-recommendation-of-hold-from-brokerages.html.

In other Mednax news, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $55.00, for a total value of $1,282,985.00. Following the transaction, the insider now directly owns 296,379 shares of the company’s stock, valued at $16,300,845. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Manuel Kadre acquired 21,704 shares of the company’s stock in a transaction on Friday, May 5th. The stock was acquired at an average cost of $55.79 per share, for a total transaction of $1,210,866.16. Following the completion of the purchase, the director now directly owns 111,255 shares of the company’s stock, valued at approximately $6,206,916.45. The disclosure for this purchase can be found here. Insiders sold 33,074 shares of company stock worth $1,830,508 over the last ninety days. Insiders own 2.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Mednax by 5.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $106,000 after buying an additional 77 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Mednax by 9.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 15,780 shares of the company’s stock valued at $1,052,000 after buying an additional 1,360 shares in the last quarter. Norges Bank purchased a new stake in shares of Mednax during the fourth quarter valued at approximately $56,794,000. Gulf International Bank UK Ltd increased its stake in shares of Mednax by 1.5% in the first quarter. Gulf International Bank UK Ltd now owns 30,620 shares of the company’s stock valued at $2,124,000 after buying an additional 450 shares in the last quarter. Finally, Fenimore Asset Management Inc. increased its stake in shares of Mednax by 7.3% in the first quarter. Fenimore Asset Management Inc. now owns 858,880 shares of the company’s stock valued at $59,589,000 after buying an additional 58,070 shares in the last quarter.

Mednax (NYSE MD) traded down 0.10% during trading on Monday, reaching $58.48. 275,258 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $56.38 and a 200-day moving average price of $64.57. The firm has a market cap of $5.40 billion, a PE ratio of 17.46 and a beta of 0.44. Mednax has a 12 month low of $53.80 and a 12 month high of $76.51.

Mednax (NYSE:MD) last issued its quarterly earnings results on Thursday, May 4th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.01. The firm had revenue of $835.60 million for the quarter, compared to analyst estimates of $837.01 million. Mednax had a net margin of 9.54% and a return on equity of 12.81%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.87 EPS. On average, analysts forecast that Mednax will post $3.58 earnings per share for the current fiscal year.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.